Ana Elvira Laffond

ORCID: 0000-0002-1553-5652
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac Valve Diseases and Treatments
  • Infective Endocarditis Diagnosis and Management
  • Cardiac pacing and defibrillation studies
  • Cardiac, Anesthesia and Surgical Outcomes
  • Atrial Fibrillation Management and Outcomes
  • Cardiac Imaging and Diagnostics
  • Cardiac Arrhythmias and Treatments
  • Acute Myocardial Infarction Research
  • Mechanical Circulatory Support Devices
  • Cardiac Structural Anomalies and Repair
  • Cardiac electrophysiology and arrhythmias
  • Cardiac tumors and thrombi
  • Antimicrobial Resistance in Staphylococcus
  • Healthcare Systems and Technology
  • Cardiovascular Function and Risk Factors
  • Patient-Provider Communication in Healthcare
  • Aortic Disease and Treatment Approaches
  • Case Reports on Hematomas
  • Nutritional Studies and Diet
  • Peripheral Artery Disease Management
  • Quality and Safety in Healthcare
  • Stress and Burnout Research
  • Bacterial Identification and Susceptibility Testing
  • Health Policy Implementation Science
  • Infectious Aortic and Vascular Conditions

Complejo Hospitalario de Salamanca
2020-2024

Instituto de Investigación Biomédica de Salamanca
2021-2024

Centro de Investigación en Red en Enfermedades Cardiovasculares
2021-2024

Universidad de Salamanca
2021-2023

Institute of Cardiology
2021

Objective Left atrial appendage (LAA) thrombus has heretofore been considered a contraindication to percutaneous LAA closure (LAAC). Data regarding its management are very limited. The aim of this study was analyse the medical and invasive treatment patients referred for LAAC in presence thrombus. Methods This multicentre observational registry included 126 consecutive with on preprocedural imaging. Treatment strategies intensification antithrombotic therapy (IAT) or direct LAAC. primary...

10.1136/heartjnl-2021-319811 article EN cc-by-nc Heart 2021-10-22

Background: Effective risk communication is crucial for managing cardiovascular disease, the leading cause of global mortality. Clear between patients and physicians essential informed decision-making, yet gaps in understanding often persist. Objective: This study examines state during hospital admissions events, evaluating both patient physician perspectives identifying factors influencing perception. Methods: The SEC-HARIPA a multicenter, cross-sectional analysis conducted across 28...

10.1101/2024.12.02.24318359 preprint EN cc-by-nd medRxiv (Cold Spring Harbor Laboratory) 2024-12-03

Abstract Funding Acknowledgements Type of funding sources: None. Dilated cardiomyopathy (DCM) is a complex myocardial disease, with high burden symptoms and decreased life expectancy. Mitral regurgitation (MR) frequent comorbid condition it thought that deteriorates left ventricle (LV) volume ejection fraction. Guideline directed medical therapy for heart failure improves function decreases morbidity mortality, there ongoing interest in the application novel percutaneous techniques like...

10.1093/ehjci/jeaa356.361 article EN European Heart Journal - Cardiovascular Imaging 2021-01-01

Abstract Introduction Transesophageal echocardiography (TOE) is the most frequently used imaging technique for intraprocedural guidance in left appendage closure interventions. However, it usually requires use general anaesthesia and implies an increased risk of bleeding, esophageal upper airway tract lesions. Intracardiac TOE with microprobes (micro-TOE) have been proposed as alternative techniques procedural imaging. Purpose The aim this study to compare results LAAC interventions terms...

10.1093/eurheartj/ehad655.127 article EN European Heart Journal 2023-11-01

Abstract Background Oral anticoagulation (OAC) use increases the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF). Left appendage occlusion (LAAO) is an alternative to OAC, however data about its prior ICH scare and timing performance controversial. Furthermore, long-term outcomes this group have not been described. Objective To evaluate safety efficacy LAAO non-valvular AF (CHA2SVASc >2) determine adequate performance. Methods The sample was obtained...

10.1093/eurheartj/ehad655.2278 article EN European Heart Journal 2023-11-01
Coming Soon ...